Olanzapine (oh-LAN-za-peen, sold as Zyprexa®, Zydis®, or in combination with fluoxetine, as Symbyax®) was the second atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder. It has also been established in treating depression off-label because of its mood-stabilizing properties and its ability to increase the efficacy of antidepressants. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company. It is available as a pill that comes in the strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg and as as Zydis orally disintegrating tablets in the strengths of 5 mg, 10 mg, 15 mg, and 20 mg. It is also available as a rapid-acting intramuscular injection for short term acute use.

Case-reports, open-label, and small pilot studies suggest efficacy of olanzapine for the treatment of some anxiety spectrum disorders (e.g. general anxiety disorder, panic disorder, post-traumatic stress disorder); however, olanzapine has not been rigorously evaluated in randomized, placebo-controlled trials for this use and is not FDA approved for these indications. Other common off-label uses of olanzapine include the treatment of eating disorders (e.g. anorexia nervosa) and as an adjunctive treatment for major depressive disorder with psychotic features.

Pharmacology

---

Olanzapine is structurally similar to clozapine, and is classified as a thienobenzodiazepine. Olanzapine has a high affinity for dopamine and serotonin receptors. Like most atypical antipsychotics compared to the older typical ones, Olanzapine has a lower affinity for histamine, cholinergic muscarinic and alpha adrenergic receptors. The mechanism of action of olanzapine is unknown, however it is theorized that olanzapine's antipsychotic activity is mediated primarily by antagonism at dopamine receptors, specifically D2. Serotonin antagonism may also play a role in the effectiveness of olanzapine, but the significance of 5-HT2A antagonism is debated among researchers. Antagonism at muscarinic, histaminic and alpha adrenergic receptors likely explains some of the side effects of olanzapine, such as anticholinergic effects, weight gain, sedation and orthostatic hypotension.

More on [ Olanzapine ]

Olanzapine - Twitter Search

@JohnnyVoiture Olanzapine?! You're lucky, my man. I have been *begging* for it (or similar), but they refuse! #nhsfail Hope it helps mate xx
Kazcita (Kaz) Sun, 08 Nov 2009 02:27:33 -0000
@JohnnyVoiture Olanzapine?! You're lucky, my man. I have been *begging* for it (or similar), but they refuse! #nhsfail Hope it helps mate xx
FUN DRUG REP LOGO FACT Lilliy gave doctors a flat magnet imprinted with "Zyprexa olanzapine www.ZYPREXA.com Lilliy"
GNRTG4gifts (GoodNReadyToGo) Sat, 07 Nov 2009 04:12:08 -0000
FUN DRUG REP LOGO FACT Lilliy gave doctors a flat magnet imprinted with "Zyprexa olanzapine www.ZYPREXA.com Lilliy"
AIT article: Mifepristone treatment of olanzapine-induced weight gain in healthy men http://tinyurl.com/ya6xlug
AIT_journal (Advances in Therapy) Fri, 06 Nov 2009 13:51:45 -0000
AIT article: Mifepristone treatment of olanzapine-induced weight gain in healthy men http://tinyurl.com/ya6xlug
A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs ... - Archives of General Psychiatr.. http://bit.ly/3NY2BZ
googlemed (Binofi) Tue, 03 Nov 2009 01:30:09 -0000
A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs ... - Archives of General Psychiatr.. http://bit.ly/3NY2BZ

Subscribe to Olanzapine RSS feed